COMP <GO>
DVA vs MRK // EV/EBITDA & P/E VALUATION
DaVita Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: DVA 7
— MRK 8
▲ EV/EBITDA & P/E VALUATION LEADER: DVA
LAST: $187.50 (-3.01%) • MKT CAP: $12.33B
valuation
7.3x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DVA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DVA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | 20.70% | +8.50 | DVA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.3x | 15.3x | -8.00 | DVA | /valuation <GO> |
| Free Cash Flow Yield | 10.63% | 3.42% | +7.21 | DVA | /fcf-yield <GO> |
| Operating Margin | 15.00% | 34.30% | -19.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 7.90% | 28.10% | -20.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 6.50% | 1.30% | +5.20 | DVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.66 | 5.19 | -3.53 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | DVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 56.9 | -2.53 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.92 | +0.03 | DVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.6x | 18.4x | -7.80 | DVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.33B | $361.02B | -$348.69B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DVA REV | MRK REV | DVA GROSS % | MRK GROSS % | DVA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.64B | $65.01B | 44.0% | 74.8% | $1.31B | $12.36B |
| FY 2024 | $12.82B | $64.17B | 44.0% | 76.3% | $1.47B | $18.10B |
| FY 2023 | $12.14B | $60.12B | 44.0% | 44.0% | $1.51B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DVA // BETA 0.95
MRK // BETA 0.92